In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
A Northwestern Medicine-led study published in the Journal of Clinical Investigation has uncovered why older individuals with specific genetic mutations face a heightened risk of developing serious ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Explore groundbreaking research on pancreatic cancer treatment that shows promise in inducing complete tumour regression.
SEER based nomograms predicted overall and cancer specific survival in acute erythroid leukemia, with age and chemotherapy ...
The FDA has granted orphan drug designation (ODD) to LP-284, a next-generation acylfulvene small molecule, for the treatment ...
In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.
Researchers have developed new prognostic nomograms using data from the Surveillance, Epidemiology, and End Results (SEER) database to better predict survival outcomes in patients with acute erythroid ...
A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the ...
Sixth overall for Lantern’s A.I.-driven precision oncology pipelineOrphan designation expands LP-284's potential for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results